INTRODUCTION {#s1}
============

Acute myeloid leukemia (AML) is a serious disease of the hematopoietic system characterized by de-differentiation and uncontrolled proliferation of immature hematopoietic precursor cells in the bone marrow \[[@R1]\]. It is usually based on many parameters including age, white blood cell count, cytogenetic abnormalities, and specific mutations \[[@R2]\]. AML results from the accumulation of genetic and epigenetic alterations during the multistep process of tumorigenesis, including activation of oncogenes and/or inactivation of tumor suppressor genes.

The Wilms' tumor gene 1 (WT1), located at chromosome 11p13, was firstly cloned in 1990 as a suppressor in Wilms' tumor \[[@R3]\]. WT1 regulates transcription, RNA metabolism, translation and both oncogenic and tumor suppressor functions \[[@R4]\]. Since the expression of WT1 in many solid cancers is upregulated, it is considered as a potential oncogene \[[@R5]\]. Although the pathogenesis of WT1 in leukemia has not been completely revealed, the phenomenon that low expression of WT1 and high expression of WT1 are accompanied with clinical remission and relapse respectively shows that WT1 may be a potential prognostic factor in acute leukemia \[[@R6]\].

Although a number of studies suggested that WT1 rs16754 polymorphism might be related to decreased relapse free survival (RFS) and overall survival (OS). The results remain controversial \[[@R7]-[@R18]\]. In this study, meta-analysis of the association between WT1 rs16754 polymorphism and OS and RFS of AML was conducted. Twelve studies involving 3903 patients with AML are pooled in the meta-analysis.

RESULTS {#s2}
=======

Characteristics of the studies {#s2_1}
------------------------------

The flow chart in Figure [1](#F1){ref-type="fig"} summarizes this literature review process. Twelve publications with 3903 AML patients had met the inclusion criteria and were included in this meta-analysis. Seven studies were conducted in Caucasians, 3 were conducted in Asians, and the remaining 2 studies were conducted in mixed ethnic groups. Two studies included child and the remaining studies included adults. Characteristics of the included studies are shown in Table [1](#T1){ref-type="table"}.

![Study flow diagram of included studies](oncotarget-07-32079-g001){#F1}

###### Characteristics of the included studies

  No.   First author   Year   Study design   Race        Age   Female (%)   Subtype              Sample size   Adjusted for OS                                                                                                                                                                     Adjusted for RFS
  ----- -------------- ------ -------------- ----------- ----- ------------ -------------------- ------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1     Damm           2010   Cohort         Caucasian   45    48           CN-AML               249           NPM1/FLT3 mutation status, age, Platelet, CEBPA mutation status, WBC                                                                                                                NPM1/FLT3 mutation status, Platelet, CEBPA mutation status, WBC
  2     Hollink        2010   Cohort         Caucasian   9     40           Mix                  272           NA                                                                                                                                                                                  NA
  3     Wagner         2010   Cohort         Caucasian   49    83           CN-AML               275           Age, IDH1 SNP rs11554137, NPM1/FLT3 mutation status, Platelets                                                                                                                      NPM1 mutation status, CEBPA mutation status
  4     Becker         2011   Cohort         Mix         62    50           CN-AML               433           NA                                                                                                                                                                                  NA
  5     Ho             2011   Cohort         Mix         10    45           NA                   790           Risk group, WBC, race                                                                                                                                                               Risk group, WBC, race
  6     Renneville     2011   Cohort         Caucasian   51    46           Mix                  511           NA                                                                                                                                                                                  NA
  7     Damm           2012   Cohort         Caucasian   47    48           CN-AML               269           ID1, age, BAALC expression, Platelets, FLT3-ITD, CEBPA mutation                                                                                                                     ID1, Platelets, NPM1 mutation, CEBPA mutation
  8     Choi           2012   Cohort         Asian       42    63           CN-AML               73            NA                                                                                                                                                                                  NA
  9     Luna           2012   Cohort         Caucasian   62    43           de novo AML          175           NPM1, FLT3-ITD, and CEBPA, expression levels of WT1, age, WBC count, platelet count, hemoglobin level, percentage of blood blasts, cytogenetic risk group, and FAB classification   NPM1, FLT3-ITD, and CEBPA, expression levels of WT1, age, WBC count, platelet count, hemoglobin level, percentage of blood blasts, cytogenetic risk group, and FAB classification
  10    Luo            2014   Cohort         Asian       45    58           de novo non-M3 AML   182           Age, percentage of blood blasts, WT1 expression, WBC, FLT3                                                                                                                          Age, percentage of blood blasts, WT1 expression, WBC, FLT3
  11    Niavarani      2015   Cohort         Caucasian   45    55           CN-AML               469           Age, sex, WBC, secondary disease, performance status, FLT3-ITD, and NPM1 mutations                                                                                                  Age, sex, WBC, secondary disease, performance status, FLT3-ITD, and NPM1 mutations
  12    Zhang          2015   Cohort         Asian       40    46           Mix                  205           Risk stratification, allogeneic hematopoietic stem cell transplantation                                                                                                             Risk stratification, allogeneic hematopoietic stem cell transplantation

Association between WT1 rs16754 polymorphism and OS of AML {#s2_2}
----------------------------------------------------------

When all eligible studies were pooled into one dataset for the meta-analysis, we found WT1 rs16754 polymorphism was significantly associated with OS in AML (OR = 0.62; 95% CI 0.52 − 0.75; *p* \< 0.00001; Figure [2](#F2){ref-type="fig"}). In the subgroup analysis of race, both Asians and Caucasians showed better OS in AML (OR = 0.61; 95% CI 0.43 − 0.85; *p* = 0.004; and OR = 0.60; 95% CI 0.44 − 0.81; *p* = 0.001). In addition, both de novo AML and CN-AML showed better OS in AML (OR = 0.40; 95% CI 0.24 − 0.67; *p* = 0.0004; and OR = 0.60; 95% CI 0.43 − 0.84; *p* = 0.001). In a further stratified analysis by age, both children and adults showed better OS in AML (OR = 0.67; 95% CI 0.51 − 0.88; *p* = 0.004; and OR = 0.60; 95% CI 0.47 − 0.75; *p* \< 0.0001). The results were showed in Table [2](#T2){ref-type="table"}.
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###### Results of the meta-analysis

                 OR (95% CI)        *P* Value   *I*^2^ (%)   *p* Value
  -------------- ------------------ ----------- ------------ -----------
  OS             0.62 (0.52-0.75)   \<0.00001   47           0.04
  Subtype                                                    
   de novo AML   0.40 (0.24-0.67)   0.0004      0            0.82
   CN-AML        0.60 (0.43-0.84)   0.003       67           0.009
  Race                                                       
   Asian         0.61 (0.43-0.85)   0.004       0            0.61
   Caucasian     0.60 (0.44-0.81)   0.001       69           0.004
  Age                                                        
   \<18 years    0.67 (0.51-0.88)   0.004       0            0.50
   \>18 years    0.60 (0.47-0.75)   \<0.0001    55           0.02
  RFS            0.69 (0.57-0.83)   \<0.001     46           0.04
  Subtype                                                    
   de novo AML   0.42 (0.26-0.68)   0.0004      0            0.49
   CN-AML        0.74 (0.62-0.88)   0.007       36           0.12
  Race                                                       
   Asian         0.61 (0.42-0.88)   0.008       0            0.65
   Caucasian     0.64 (0.49-0.85)   0.002       63           0.001
  Age                                                        
   \<18 years    0.74 (0.55-1.00)   0.05        0            0.50
   \>18 years    0.68 (0.54-0.85)   0.0006      55           0.02

Association between WT1 rs16754 polymorphism and RFS of AML {#s2_3}
-----------------------------------------------------------

As for RFS of AML, WT1 rs16754 polymorphism was found to be significantly associated with RFS (OR = 0.69; 95% CI 0.57 − 0.83; *p* \< 0.001; Figure [3](#F3){ref-type="fig"}). In the subgroup analysis of race, both Asians and Caucasians with this polymorphism exhibited better RFS in AML (OR = 0.61; 95% CI 0.42 − 0.88; *p* = 0.008; and OR = 0.64; 95% CI 0.49 − 0.85; *p* = 0.002). In terms of AML subtype, both de novo AML and CN-AML displayed better RFS in AML (OR = 0.42; 95% CI 0.26 − 0.68; *p* = 0.0004; and OR = 0.74; 95% CI 0.62 − 0.88; *p* = 0.007). In the stratified analysis by age, a significantly better RFS was found among children (OR = 0.74; 95% CI 0.55 − 1.00; *p* = 0.05), and was also found among adults (OR = OR = 0.68; 95% CI 0.54 − 0.85; *p* = 0.0006). The results were listed in Table [2](#T2){ref-type="table"}.
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Sensitivity analyses and publication bias {#s2_4}
-----------------------------------------

The results of sensitivity analyses showed that the estimates before and after the deletion of each study were similar (Figures [4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}). The shapes of the funnel plot seemed symmetrical (Figures [6](#F6){ref-type="fig"} and [7](#F7){ref-type="fig"}), suggesting that there was no obvious publication bias.
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DISCUSSION {#s3}
==========

Many studies have investigated the relation of WT1 rs16754 polymorphism with prognosis of AML, but the conclusions are still controversial. In view of this issue, we comprehensively analyzed the association between WT1 rs16754 polymorphism and OS or RFS of AML via the method of meta-analysis, and found that WT1 rs16754 polymorphism affected the survival of AML. Thus, WT1 rs16754 polymorphism might be a prognostic factor of AML.

WT1 expression is detectable in CD34+ progenitor cells, but is down-regulated during the process of hematopoietic differentiation, and undetectable in mature leukocytes \[[@R19]\]. WT1 overexpression could be observed in the majority of AML patients at diagnosis, which disappeared when complete remission (CR) was achieved by chemotherapy. Hence, WT1 expression has been regarded as a potential biomarker for the detection of minimal residual dis-ease (MRD) in clinic \[[@R20]\]. Ujj et al. also suggested that disappearance of WT1-positivity during chemotherapy had a favorable effect on survival \[[@R21]\]. Casalegno-Garduño et al. indicated that WT1 is a suitable marker for the detection of minimal residual disease after SCT or chemotherapy \[[@R22]\]. Recently, analysis of WT1 expression in circulating RNA in plasma in AML patients could be a simple, convenient and noninvasive method to predict latent information about relapse \[[@R23]\]. WT1 rs16754 polymorphism consists in a change ofthe nucleotide adenine (A) into guanine (G). Zhang et al. found that the WT1 GG patients showed significantly higher WT1 mRNA expression than the WT1 GA/AA patients \[[@R18]\]. Thus, it might be the reason for why WT1 rs16754 polymorphism could influence the survival of AML.

We performed sensitivity analysis by excluding studies to verify the stability of results. However, this present study also has some limitations. First, the sample size was relatively small in subgroup analyses. Second, significant heterogeneity was detected in included studies and the accuracy of results would be affected in spite of utilizing the random-effects model to calculate pooled ORs. Third, we didn\'t explore gene-gene and gene-environment interactions because of the insufficient data. Finally, this study is a meta-analysis of case-control study and cohort study. Confounding cannot be avoided and should be considered.

In conclusion, WT1 rs16754 polymorphism is associated with better survival of AML. It could be used as a cost-effective prognostic biomarker for AML.

MATERIALS AND METHODS {#s4}
=====================

Publication search {#s4_1}
------------------

Published reports were searched in PubMed, EMBASE, and Google Scholar, with the following key words: "acute myeloid leukemia" and "Wilms' tumor gene 1". The MeSH terms, such as "leukemia, myeloid, acute" and "genes, wilms tumor", were used. Publication language was not restricted in this search. Reference lists of articles retained for review were examined manually to further identify potentially relevant reports.

Study selection {#s4_2}
---------------

Two reviewers independently screened the abstracts of papers identified by the literature search, retrieved potentially relevant studies and determined study eligibility. Studies were included if: (1) study design was prospective or retrospective cohort study; (2) the exposure of interest was WT1 rs16754 polymorphism; (3) the studied reported relative risks (RRs), hazard ratios (HRs), or odds ratios (ORs) with corresponding 95% confidence intervals (CIs); and (4) the outcome was RFS or OS. If the same cohort was used in more than one publication, we included the publication that reported the results in greater detail or, if similar, the one with the largest number of cases. Data published only in abstract form were excluded. Case reports, review articles and commentary articles were also excluded.

Data extraction {#s4_3}
---------------

The following data including: the first author, year, study design, ethnicity of the study population, age, sex, subtype, number of patients included in analysis, adjusted factors, and OR with its 95% CI for OS and RFS were extracted from each eligible study by two investigators.

Statistical analysis {#s4_4}
--------------------

The strength of association between WT1 rs16754 polymorphism and RFS and OS of AML was evaluated by calculating the OR and 95% CI. To assess the significance of OR, we conducted the Z test and we regarded it as significant difference when P value less than 0.05 was detected. Moreover, X2 based Q and I2 test were performed to evaluate the between-study heterogeneity and P\<0.1 was defined as statistical significance. The random-effects was used to calculated the OR if significant heterogeneity existed. Otherwise, the fixed-effects model was applied. Furthermore, we also conducted subgroup analyses stratified by ethnicity (Caucasian and Asian), age (child and adult), and subtype of AML. Publication bias was assessed by asymmetry of funnel plots. In sensitivity analysis, we sequentially excluded each study on the software to evaluate the stability of the results. We conducted all the analyses by using software Review Manager 5.1 (Nordic Cochrane Center, Copenhagen, Denmark) and STATA 11.0 software (Stata Corporation, College Station, TX, USA).
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